In the last trading session, 3.84 million shares of the Akebia Therapeutics Inc (NASDAQ:AKBA) were traded, and its beta was 0.97. Most recently the company’s share price was $3.63, and it changed around $0.01 or 0.28% from the last close, which brings the market valuation of the company to $953.37M. AKBA currently trades at a discount to its 52-week high of $4.08, offering almost -12.4% off that amount. The share price’s 52-week low was $0.91, which indicates that the current value has risen by an impressive 74.93% since then. We note from Akebia Therapeutics Inc’s average daily trading volume that its 10-day average is 4.4 million shares, with the 3-month average coming to 5.07 million.
Akebia Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended AKBA as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight.
Akebia Therapeutics Inc (NASDAQ:AKBA) trade information
Instantly AKBA has showed a green trend with a performance of 0.28% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 3.77 on recent trading dayincreased the stock’s daily price by 3.71%. The company’s shares are currently up 278.13% year-to-date, but still down -0.55% over the last five days. On the other hand, Akebia Therapeutics Inc (NASDAQ:AKBA) is -0.27% down in the 30-day period. We can see from the shorts that 18.5 million shares have been sold at a short interest cover period of 3.02 day(s).
The consensus price target as assigned by Wall Street analysts is $6.5, which translates to bulls needing to increase their stock price by 44.15% from its current value. Analyst projections state that AKBA is forecast to be at a low of $6 and a high of $7.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 32.58%.
AKBA Dividends
Akebia Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-May-08.
Akebia Therapeutics Inc (NASDAQ:AKBA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 3.59% of Akebia Therapeutics Inc shares, and 38.87% of them are in the hands of institutional investors. The stock currently has a share float of 40.31%. Akebia Therapeutics Inc stock is held by 188.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 5.5499% of the shares, which is about 11.64 million shares worth $11.87 million.
VANGUARD GROUP INC, with 4.4235% or 9.28 million shares worth $9.46 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
